Apparent lack of correlation between tyramine and phenylethylamine content and the occurrence of food-precipitated migraine - Reexamination of a variety of food products frequently consumed in the United States and commonly restricted in tyramine-free diets

Headache Quarterly

Volumn 7, Issue 3, 1996, Pages 239-249

  Mosnaim, Aron D ^a,h   Freitag, Frederick G ^b,c   Ignacio, Romeo ^a   Salas, Marco A ^a   Karoum, Farouk ^d   Wolf, Marion E ^e,f   Diamond, Seymour ^a,g  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b DIAMOND HEADACHE CLINIC   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Diamond Inpatient Headache Unit   (United States)

^h FUHS/CMS   (United States)

Author keywords

Diet precipitated headaches; Phenylethylamine; Tyramine

Indexed keywords

PHENETHYLAMINE; TYRAMINE;

ARTICLE; DIET RESTRICTION; FOOD COMPOSITION; HUMAN; MIGRAINE; PRIORITY JOURNAL; UNITED STATES;

EID: 0029757957     PISSN: 10597565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol. 1969; 21:263-268.
2. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet. 1963; ii:733-734.
3. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Oilman AG, eds). New York: McGraw-Hill; 1996; 399-460.
4. Blackwell B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet. 1963; ii:849-851.
5. _ Mabbit LA. Tyramine in cheese related to hypertensive crisis after monoamine-oxidase inhibition. Lancet. 1965; i:938-940.
6. Dalessio DJ, Silberstein SD (eds). Wolff's Headache and Other Head Pain, 6th edition. New York: Oxford University Press; 1993.
7. Davies EB. Tranylcypromine and cheese. Lancet. 1963; ii:691-692.
8. Diamond S. Headaches. In: Conn's Current Therapy 1992 (Rakel R, ed). Philadelphia: WB Saunders; 1991; 834-848.
9. _ Head pain. Diagnosis and management. Clin Symp (CIBA). 1994; 46:4-19.
10. _ Francis D, Diamond Vye A. Headache and Diet: Tyramine-free Recipes. Madison, CT: International Universities Press; 1992.
11. Folks DG. Monoamine oxidase inhibitors: Reappraisal of dietary considerations. J Clin Psychopharmacol. 1983; 3:249-252.
12. Freitag FG, Diamond S, Solomon GD. Antidepressants in the treatment of mixed headache: MAO inhibitors and combined use of MAO inhibitors and tricyclic antidepressants in the recidivist headache patient. In: Advances in Headache Research (Rose FC, ed). London: John Libbey; 1987; 271-275.
13. Gardner D, Shulman KI, Walker SE, Tailor S. The making of a user friendly MAOI diet. J Clin Psychiat. 1996:57:99-104.
14. Hanington E. Preliminary report on tyramine headache. Br Med J. 1967; ii:550-551.
15. _ Monoamine oxidase and migraine. Lancet. 1974; ii:1148-1150.
16. Hansen TR, Greenberg J, Mosnaim AD. Direct effect of phenylethylamine upon isolated vascular smooth muscle of the rat. Eur J Pharmacol. 1980; 63:95-101.
17. Hare ML. Tyramine oxidase: New enzyme in liver. Biochem J. 1928; 22:968-979.
18. Inwang EE, Mosnaim AD, Sabelli HC. Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J Neurochem. 1973; 20:1469-1473.
19. Karoum F. Combined gas chromatography-mass spectrometry in the analysis of biogenic amines in humans. In: Neuromethods 2 (Series I, Neurochemistry. Amines and Their Metabolites (Boulton A, Baker G, Baker J, eds). Clifton NJ: Humana Press; 1985; 305-232.
20. Lurie ML, Salzer HM. Tranylcypromine (Parnate) in the ambulatory treatment of depressed patients. Am J Psychiat. 1986; 118:152-155.
21. McCabe BJ. Dietary tyramine and other pressor amines in MAOI regimens: A review. J Am Diet Assoc. 1986; 86:1059-1064.
22. _ Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiat. 1982; 43:178-181.
23. Mosnaim AD. Biochemical and immunological studies in migraine and cluster headaches. Headache Quart. 1994; 5:34-38.
24. _ Wolf ME (eds). Noncatecholic Phenylethylamines. Part 1. Phenylethylamine: Biological Mechanisms and Clinic Aspects. New York: Marcel Dekker; 1978.
25. _ (eds). Noncatecholic Phenylethylamines. Part 2. Phenylethylamine, Tyramines and Octopamine. New York: Marcel Dekker; 1980.
26. _ Wine R, Karoum F, Diamond S, Wolf ME. Methionine-enkephalin, phenylethylamine, phenylacetic acid, monoamine oxidase activity, and prolactin in plasma of migraine patients. Clin Pharmacol Ther. 1982a; 31:251-252.
27. _ Karoum F, Zeller EA, Callaghan OH, Singh SP, Wolf ME. Platelet monoamine oxidase activity and plasma levels of non-catecholic phenylethylamines in insulin-dependent diabetic subjects. Clin Chim Acta. 1982b; 126:237-242.
28. _ Diamond S, Wolf ME, Puente J, Freitag FG. Endogenous opioid-like peptides in headache. An overview. Headache. 1989; 29:368-372.
29. _ Huprikar S, Wolf ME, Callaghan OH, Freitag FG, Diamond S. Platelet monoamine oxidase activity in cluster headache patients. Headache Quart. 1992; 3:172-176.
30. Wolf ME, Maturana P, Puente J, Freitag FG, Diamond S. In vitro studies of natural killer cell activity in migraineurs. Changes in response to a β-endorphin challenge during an acute migraine episode. Headache Quart. 1994; 5:142-149.
31. _ Curr M, Mosnaim J, Freitag FG; Diamond S. Myths in headache research: 1. Migraine and cluster headache patients are characterized by significant alterations in platelet monoamine oxidase activity. Headache Quart. 1996; 7:225-234.
32. Peatfield R. Headaches. Berlin: Springer-Verlag; 1986.
33. Perkins JE, Hartje J. Diet and migraine. A review of the literature. J Am Diet Assoc. 1983; 83:459-463.
34. Sandyk R, Iacono RP. Phenelzine in migraine headaches. Int'l J Neurosci. 1987; 35:243. (Letter)
35. Sheehan D, Claycomb J, Kouretas N. Monoamine oxidase inhibitors: Prescription and patient management. Int'l J Psychiat Med. 1980; 19:99-121.
36. Shulman KI, Walker SE, Mackenzie S, Knowles D. Dietary restriction, tyramine and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989; 9:397-402.
37. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: A re-examination. Can J Psychiat. 1984; 29:707-711.
38. Sweet RA, Brown EJ, Heimberg RG, Ciafre L, Scanga DM, Cornelius JR, et al. Monoamine oxidase inhibitor dietary restrictions: What are we asking patients to give up? J Clin Psychiat. 1995; 56:196-201.
39. Tailor S, Shulman KI, Walker SE, Moss J, Gardner D. Hypertensive episode associated with phenelzine and tap beer - A re-analysis of the role of pressor amines in beer. J Clin Psychopharmacol. 1994; 14:5-14.
40. Van der Bergh V, Amery WK, Waelkens J. Trigger factor in migraine: A study conducted by the Belgian Migraine Society. Headache. 1987; 27:191-196.
41. Wolf ME, Mosnaim AD. Mini review: Phenylethylamine in neuropsychiatric disorders. Gen Pharmacol. 1983; 14:385-390.
42. Yashuhara H, Parvez SH, Sandler M, Nogatsu T (eds). Monoamine Oxidase: Basic and Clinical Aspects. Utrecht: VSP; 1993.
43. Zeller EA, Barsky B. In vivo inhibition of liver and brain monoamine oxidase by i-isonicotinyl-z-isopropyl hydrzine. Proc Soc Exper Biol Med. 1952; 81:459-461.